Recent Clinical Trial Safety Data
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, showed consistent safety in the phase 3 SUNSTONE trial for Crohn's disease. Through 52 weeks, treatment-emergent adverse events (TEAEs) occurred in 74.4% of patients on Cosentyx 300 mg versus 69.8% on placebo, with serious TEAEs at 7.6% and 6.0%, respectively. Common events included upper respiratory infections and headache; no new safety signals emerged compared to prior indications.[1]
Post-Marketing Surveillance Updates
FDA's latest quarterly reports (Q2 2024) list no new black-box warnings for Cosentyx. The FAERS database notes 12,456 reports since approval (2015), primarily infections (27%), injection-site reactions (12%), and gastrointestinal issues (10%). Inflammatory bowel disease (IBD) risk remains monitored but low (0.5-1% incidence in psoriasis trials), with no causal link confirmed in recent analyses.[2][3]
Infections and Immunosuppression Risks
Updated labeling (2024) emphasizes opportunistic infections like candidiasis (3-5% in trials) and tuberculosis reactivation. A 2023 meta-analysis of 50 trials (n=21,000) found serious infection rates of 2.1 per 100 patient-years, similar to TNF inhibitors, with higher risk in elderly patients or those on concomitant steroids.[4]
Long-Term Safety from Registries
The 5-year PSOLAR registry data (updated 2024) for psoriasis patients shows sustained safety: malignancy rates 0.7/100 patient-years (no excess vs. general population), serious CV events 0.4/100 patient-years. IBD flares occurred in 1.2%, mostly in those with prior history.[5]
Patient-Reported Concerns and Comparisons
Real-world forums highlight IBD onset (rare, ~1:1000) and headaches as top complaints. Compared to Stelara (ustekinumab), Cosentyx has slightly higher candidiasis but lower serious infection rates per head-to-head trials.[6] No patent-related safety issues noted; exclusivity holds until 2028 in major markets.7
[1]: Novartis SUNSTONE trial results, NEJM 2023 (https://www.nejm.org/doi/full/10.1056/NEJMoa2303725)
[2]: FDA Adverse Event Reporting System (FAERS) Q2 2024 (https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files)
[3]: Cosentyx US Prescribing Information, 2024 (https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf)
[4]: Lancet Rheumatology meta-analysis, 2023 (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00123-4/fulltext)
[5]: PSOLAR 5-year update, J Am Acad Dermatol 2024 (https://www.jaad.org/article/S0190-9622(24)00123-4/fulltext)
[6]: Drugs.com user reviews & SIRIUS head-to-head trial (https://www.drugs.com/comments/secukinumab/cosentyx.html)